Therapies for Advanced Colorectal Cancer: The Role of Interferon and Leucovorin

1997 ◽  
Vol 83 (1_suppl1) ◽  
pp. 67-69 ◽  
Author(s):  
John S. Macdonald
Keyword(s):  
Colorectal Cancer ◽  
Advanced Colorectal Cancer

Role of aflibercept in the treatment of advanced colorectal cancer

2014 ◽  
Vol 3 (1) ◽  
pp. 27-40
Author(s):  
Marian Gil Delgado ◽  
François Michel Delgado ◽  
David Khayat
Keyword(s):  
Colorectal Cancer ◽  
Advanced Colorectal Cancer

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis

2015 ◽  
Vol 51 (5) ◽  
pp. 587-594 ◽  
Author(s):  
Filippo Pietrantonio ◽  
Fausto Petrelli ◽  
Andrea Coinu ◽  
Maria Di Bartolomeo ◽  
Karen Borgonovo ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Advanced Colorectal Cancer ◽  
Meta Analysis ◽  
Braf Mutations ◽  
Predictive Role

scholarly journals Advances in immunotherapy for colorectal cancer: a review

2020 ◽  
Vol 13 ◽  
pp. 175628482091752 ◽  
Author(s):  
Gol Golshani ◽  
Yue Zhang
Keyword(s):  
Colorectal Cancer ◽  
Literature Review ◽  
Cancer Survival ◽  
Advanced Colorectal Cancer ◽  
Advanced Disease ◽  
Survival Rates ◽  
Cancer Treatments ◽  
Gastrointestinal Malignancies ◽  
Current Role

Immunotherapy is a new and exciting modality of cancer treatments. Its role in gastrointestinal malignancies has been promising, especially in advanced disease. Although various therapies are available for treatment of advanced colorectal cancer, survival rates for these patients remain very poor. The application of immunotherapy in colorectal cancer has shown remarkable results for a subset of patients with mismatch-repair-deficient mutations or microsatellite instability in their tumors. This literature review evaluates the current role of immunotherapy in advanced colorectal cancer, potential challenges clinicians face with immunotherapy-based regimens, and the possible future approach of combined modality immunotherapy.

scholarly journals The role of mitomycin C in the treatment of patients with advanced colorectal cancer resistant to 5-fluorouracil-folinic acid chemotherapy

2001 ◽  
Vol 12 (4) ◽  
pp. 575 ◽  
Author(s):  
S.A. Grumett ◽  
V.R. Archer ◽  
R. Midgley ◽  
P. Mulholland ◽  
S. Nicum ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Folinic Acid ◽  
Mitomycin C ◽  
Advanced Colorectal Cancer

The Potential Role of Tomudex in the Treatment of Advanced Colorectal Cancer

1997 ◽  
Vol 83 (2) ◽  
pp. 576-580 ◽  
Author(s):  
Alberto F. Sobrero
Keyword(s):  
Colorectal Cancer ◽  
Treatment Outcome ◽  
Potential Role ◽  
Advanced Colorectal Cancer ◽  
Toxicity Profile ◽  
Pros And Cons ◽  
Synthase Inhibitor ◽  
Near Future

Aims and Background The quinazoline folate analog thymidylate synthase inhibitor, Tomudex, is about to enter the Italian pharmaceutical market. Its place among the therapeutic options for advanced colorectal cancer is discussed. Methods The pros and cons of currently available chemotherapeutic regimens are briefly described with special attention to patient's and tumor's determinants of treatment outcome. The mechanism of action and the results of phase I, II and III studies of Tomudex are reviewed. Results Not all patients need to be treated. Guidelines are given in this respect. Tomudex at the dose of 3 mg/m2 given i.v. every three weeks has antitumor activity similar to that of currently available regimens, with a favorable toxicity profile. Conclusions Current research approaches are unlikely to dramatically improve the treatment outcome of this disease in the near future. What can reasonably be expected is less toxicity and more convenient routes and schedules of drug administration that may translate into better quality of life for our patients. Tomudex has been devised along these lines.

Sign in / Sign up

Export Citation Format

Share Document